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THE CLINICAL EFFECTIVENESS OF JOINT PROTECTION EDUCATION AND
EXERCISES IN HAND OSTEOARTHRITIS (OA)
K. Dziedzic 1, E. Nicholls 1, S. Hill 1, A. Hammond 2, S. Jowett 1,3,
R. Oppong 3, E.M. Hay 1. 1Arthritis Res. UK Primary Care Ctr., Keele
University, United Kingdom; 2Ctr. for Hlth., Sport & Rehabilitation Res.,
University of Salford, United Kingdom; 3 Sch. of Hlth.and Population Sci.,
University of Birmingham, United Kingdom
Purpose: This multicentre 2x2 factorial randomised controlled trial
compared; the effectiveness of joint protection education with no
joint protection; and the effectiveness of hand exercises with no
exercises.
Methods: Participants aged 50 years and over from 5 general practices
in North Staffordshire and Cheshire, UK, were mailed a screening
questionnaire (n¼12,297). Those fulﬁlling the trial eligibility criteria
were invited to attend a clinical assessment for a further eligibility
screen for the presence of hand or thumb base OA (ACR clinical
criteria). Participants giving informed consent were randomised (with
allocation concealment) using computer generated permuted blocks
stratiﬁed by GP practice, to one of four treatment interventions (leaﬂet
and advice alone; joint protection education; hand exercises; or joint
protection education and hand exercises combined). Participants with
inﬂammatory arthritis were excluded. The interventions were deliv-
ered by occupational therapists (OTs) to groups of 4-6 participants in 4
sessions over 4 weeks. The primary outcome measure was the OARSI/
OMERACT responder criteria combining hand pain and disability
(measured using the AUSCAN) and global improvement at 6 months
post-randomisation (primary end point). Secondary outcomes
included grip strength, arthritis self-efﬁcacy for pain and EUROQoL
EQ-5D. Outcomes were collected blind to treatment allocation and
were measured at 0, 3, 6 and 12 months. The main analysis was on an
intention to treat basis after adjusting for key baseline covariates and
imputation of missing data.
Results: Of 257 participants randomised (mean age (SD) 66 (9.1) yrs;
Female 66%) there was 85% follow up at 6m (n¼212) (90% at 3m; 85% at
12m). Recruitment was balanced across the groups (no joint protection n¼
130, joint protection n ¼ 127; no hand exercises n ¼ 127, hand exercises n
¼ 130). Of those randomised to OT classes, 72% attended at least 3 sessions.
At 6m, 32% were classed as responders to joint protection and 19% to no
joint protection (p¼0.02); 28% were responders to hand exercises and 22%
to no hand exercises (n.s.). There were no statistically signiﬁcantdifferences in responder criteria at 3m or 12m. There were no consistently
statistically signiﬁcant differences in any of the secondary outcome
measures at any time point, with the exception of self-efﬁcacy for pain
where differences favoured joint protection compared with no joint
protection (3m, p¼0.01; 6m, p¼0.008; 12m, p¼0.06). No adverse treat-
ment events were reported.
Conclusion: A four-week programme of joint protection provided for older
adults with hand OA afforded improvements in symptoms at 6-months
only and self-efﬁcacy at each follow-up time-point. However, no affect on
symptoms was seen for the hand exercise programme. The cost effec-
tiveness of these interventions can now be determined and ﬁndings will
add to the current evidence base for supporting self-management of hand
OA.
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KNEE JOINT SPACE WIDTH PROGRESSION: RESULTS OF A 3.3 YEARS
RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL WITH HYALURONIC
ACID. THE AMELIA PROJECT.
F. Navarro-Sarabia 1, F.J. Toyos 1, G. Herrero-Beaumont 2, P. Coronel 3,
M. Gimeno 3, B. Hernández-Cruz 1. 1Hosp. Virgen Macarena, Sevilla, Spain;
2 Fundación Jiménez Díaz, Madrid, Spain; 3 Tedec Meiji Farma SA, Alcalá de
Henares, Spain
Purpose: To study the capacity of hyaluronic acid to reduce the progres-
sion of knee osteoarthritis based on changes in Joint Space Width (JSW)
within the scope of the AMELIA (Arthrosis Modifying Effects of Long-term
Intra-articular Adant) project.
Methods: Patients with primary knee osteoarthritis (ACR criteria),
radiological grades II-III according to Kellgren scale and joint space
width >¼2 mm were randomised 1:1 to receive 4 cycles of 5 intra-
articular Adant or placebo injections each during a study period of 40
months. OMERACT-OARSI 2004 responder criteria were used for efﬁ-
cacy evaluation. Knee X-Rays were obtained using a modiﬁed protocol
of metatarsophalangeal (MTP) positioning at baseline and at month 14,
27 and 40 by technicians previously trained. X-Rays were sent to
a central laboratory where they were assessed for quality. If necessary,
repeated X-rays were requested. Approved ﬁlms were digitalized and
read in triplicate in a blind manner by the same trained reader through
the study with a semi automated computer assisted system following
a standardized procedure (EULAR 2004). The reliability of the method
was conﬁrmed before the beginning of the study and it was reassessed
at the end.
Results: Out of the 203 patients completing the study procedures, 183
patients had X-rays at both the beginning and the end of the study.
Both groups were comparable at baseline in terms of OA characteris-
tics (Table 1). Out of the 203 patients completing the study proce-
dures, 183 patients had X-rays at both the beginning and the end of
the study. Globally, the analysis of JSW reduction did not demonstrate
differences between both groups (p¼0.77). However, radiographic
progression was signiﬁcantly lower in OMERACT-OARSI responders
than in non responders, independently of the group they were
randomized (0.51 vs 0.73 mm).
A post hoc analysis was performed in a group of 55 patients with
baseline JSW >¼4mm (Nevitt et al, 2007). In spite of the small sample
size, it was observed that clinical improvement (OMERACT-OARSI
2004) in Adant patients is statistically associated with a lower
reduction of JSW which is not detected in placebo group (p¼0.027).
(Figure 1)
Conclusions: Globally, no differences in radiographic progression were
detected between groups.
In the subset of patients with preserved JSW at baseline (4mm),
a smaller reduction of JSW was observed in the OMERACT-OARSI
responders treated with Adant. This correlation was not observed in
placebo patients. These promising results deserve further research
adequately powered.
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EVALUATION OF THE EFFECT OF ADDING CORTICOSTEROID TO
VISCOSUPPLEMENTATION: A PROSPECTIVE AND RANDOMIZED STUDY
G.C. Campos, M.U. Rezende, A.F. Pailo, R. Frucchi, T. Pasqualin. IOT - FMUSP,
São Paulo, Brazil
Purpose: The aim of this study is to assess if we can improve the initial
results of viscosupplementation by the addition of corticosteroids to the
procedure, watching for any interference on the long-term results.
Methods:We evaluated 104 patients with knee osteoarthritis (OA), treated
at the group for the treatment of osteometabolic diseases of IOT-FMUSP,
São Paulo. All patients were receiving usual care for OA, and those who
underwent to any kind of intraarticular injection or knee surgery in the last
6 months, or presented post-traumatic or rheumatoid arthritis were not
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Results
SCORE WEEK MEAN (Group 1) SD (Group 1) Conﬁdence interval (95%) N (Gr
WOMAC 0 50,21 16,15 45,71 - 54,71 52
WOMAC 1 45,83 18,52 40,67 - 50,98 52
WOMAC 4 39,00 17,87 33,97 - 44,03 51
WOMAC 12 34,48 19,25 28,76 - 40,19 46
WOMAC 24 36,72 19,05 31,06 - 42,37 46
VAS 0 67,27 20,08 61,68 - 72,86 52
VAS 1 55,29 26,52 47,91 - 62,67 52
VAS 4 50,41 24,10 43,63 - 57,19 51
VAS 12 46,22 26,18 38,44 - 53,99 46
VAS 24 49,41 21,94 42,74 - 56,08 44
LEQUESNE 0 13,24 3,85 12,17 - 14,31 52
LEQUESNE 1 11,86 4,05 10,74 - 12,99 52
LEQUESNE 4 10,96 4,13 9,80 - 12,12 51
LEQUESNE 24 10,32 4,27 9,02 - 11,62 44included into the protocol. We applied the visual analogic scale of pain
(VAS) and the algofunctional questionnaires WOMAC and Lequesne.
Patients were randomized into two groups of 52 patients each. Group 1
received a single intraarticular injection of the knee with 6ml of Synvisc
One (Hylan GF-20) alone. Patients in group 2 received an intraarticular
injection of the knee with 6ml of Synvisc One (Hylan GF-20) and 1ml
(20mg) of Hexacetonide Triamcinolone. The questionnaires were applied
prior to the injection (week zero) and at weeks 1, 4, 12 and 24 after the
procedure.
This study was aproved by the University of São Paulo Clinics Hospital's
ethics committee and entirely funded by FAPESP (Cientiﬁc research
support foundation) - Grant number 2010/11450-9. It can be accessed at
clinicaltrials.com.
Results: The patient's characteristics of the two groups were compared
with chi-square and Fisher's exact tests and were considered homogeneus.
Most patiens were female (76%). The mean age was 62,7 years old. The
average BMI of patients was 29.52. Most patients (34,6%) had a level 3
Kellgreen and Lawrence radiological classiﬁcation for knee OA.
The pre-injection scores were:
Group 1- WOMAC ¼ 50,21 (SD ¼ 16,15); VAS ¼ 67,27 (SD ¼ 20,08);
Lequesne ¼ 13.24 (SD ¼ 3,85).
Group 2- WOMAC ¼ 54,54 (SD ¼ 17,58); VAS ¼ 70,21 (SD ¼ 23,59);
Lequesne ¼ 13.86 (SD ¼ 4,18). These results were statistically compared
and there was no statistic difference between groups.
At Week 1, Group 2 showed a marked reduction for WOMAC and VAS
scores, with a statistically signiﬁcant difference compared with week zero
and also when compared with Group 1 week one results. At week 4, group
2 still had better results for WOMAC and VAS compared to group 1, but
with a p>0,05.
TheWOMAC and VAS results for weeks 12 and 24were similar within the 2
groups.
The Lequesne results had no statistically signiﬁcant difference between the
2 groups at any moment. However, each group had a statistically signiﬁ-
cant improvement at weeks 1, 4, 12 and 24 compared to the baseline.
Results are shown in tables and graphics below:oup 1) MEAN (Group 2) SD (Group 2) Conﬁdence interval (95%) N (Group 2)
54,54 17,58 49,65 - 59,43 52
34,38 20,04 28,81 - 39,96 52
31,75 17,58 26,86 - 36,64 52
36,43 16,50 31,58 - 41,27 47
38,11 16,72 33,20 - 43,01 47
70,21 23,59 63,64 - 76,78 52
38,52 24,65 31,66 - 45,38 52
37,40 25,24 30,38 - 44,43 51
46,70 23,51 39,71 - 53,68 47
50,15 23,46 43,26 - 57,04 47
13,86 4,18 12,69 - 15,02 52
10,93 4,73 9,61 - 12,25 52
9,70 4,12 8,55 - 10,85 52
11,45 3,70 10,36 - 12,53 47
